Amylyx Pharmaceuticals

Yahoo Finance • last month

Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 24, Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stated that the final subject in the Phase 3 Lucidi... Full story

Yahoo Finance • 2 months ago

Pre-Market Earnings Report for March 3, 2026 : AZO, TGT, SE, VIK, ONON, BBY, THO, SRRK, SRAD, KTB, MRX, AMLX

The following companies are expected to report earnings prior to market open on 03/03/2026. Visit our Earnings Calendar for a full list of expected earnings releases. AutoZone, Inc. (AZO)is reporting for the quarter ending February 28,... Full story

Yahoo Finance • 5 months ago

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which p... Full story

Yahoo Finance • 5 months ago

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow?

Key Points Austin-based Saturn V Capital Management added 1.3 million shares of Amylyx Pharmaceuticals in the third quarter. The overall position increased in value by $41.2 million from quarter to quarter. Saturn V now holds 4.6 million... Full story

Yahoo Finance • 5 months ago

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets

Key Points Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter. Saturn V now holds nearly 2.7 mill... Full story

Yahoo Finance • 6 months ago

December 2026 Options Now Available For Amylyx Pharmaceuticals (AMLX)

Investors in Amylyx Pharmaceuticals Inc (Symbol: AMLX) saw new options become available today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so... Full story

Yahoo Finance • 6 months ago

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) - Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 6 months ago

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 6 months ago

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 7 months ago

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 7 months ago

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Amylyx Pharmaceuticals,... Full story

Yahoo Finance • 7 months ago

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 7 months ago

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to sha... Full story

Yahoo Finance • 7 months ago

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc.... Full story

Yahoo Finance • 7 months ago

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX): Grabar Law Office is investigating claims on behalf of shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) as securities fraud class a... Full story

Yahoo Finance • 8 months ago

Amylyx Pharmaceuticals prices $175M public offering

* Amylyx Pharmaceuticals (NASDAQ:AMLX [https://seekingalpha.com/symbol/AMLX]) priced [https://seekingalpha.com/pr/20227278-amylyx-pharmaceuticals-announces-pricing-of-175-million-underwritten-public-offering-of] an underwritten public of... Full story

Yahoo Finance • 8 months ago

Amylyx drops clinical program for neuro disorder after trial readout

[Isolated Document Red X Error Cancelled] Anton Zacon/iStock via Getty Images * Amylyx Pharmaceuticals (NASDAQ:AMLX [https://seekingalpha.com/symbol/AMLX]) announced on Wednesday that it has decided to discontinue a clinical program tar... Full story

Yahoo Finance • 8 months ago

Amylyx Pharmaceuticals discontinues ORION program for AMX0035 in PSP

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), currently trading at $9.16 and showing a remarkable 330% return over the past year, announced Wednesday that it is discontinuing the ORION program evaluating AMX0035 in adults with progressive su... Full story

Yahoo Finance • 9 months ago

Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline

Earnings Call Insights: Amylyx Pharmaceuticals (AMLX) Q2 2025 MANAGEMENT VIEW * Co-CEO Justin B. Klee highlighted "meaningful progress across our clinical programs" in the first half of 2025, emphasizing Avexitide as the lead asset, wh... Full story

Yahoo Finance • 9 months ago

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted

AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX [https://www.chartmill.com/stock/quote/AMLX]) REPORTS Q2 2025 EARNINGS: EPS IN LINE, MARKET REACTION MUTED Amylyx Pharmaceuticals Inc released its second-quarter 2025 financial results, posting a ne... Full story